Machine learning and optical coherence tomography-derived radiomics analysis to predict persistent diabetic macular edema in patients undergoing anti-VEGF intravitreal therapy

J Transl Med. 2024 Apr 16;22(1):358. doi: 10.1186/s12967-024-05141-7.

Abstract

Background: Diabetic macular edema (DME) is a leading cause of vision loss in patients with diabetes. This study aimed to develop and evaluate an OCT-omics prediction model for assessing anti-vascular endothelial growth factor (VEGF) treatment response in patients with DME.

Methods: A retrospective analysis of 113 eyes from 82 patients with DME was conducted. Comprehensive feature engineering was applied to clinical and optical coherence tomography (OCT) data. Logistic regression, support vector machine (SVM), and backpropagation neural network (BPNN) classifiers were trained using a training set of 79 eyes, and evaluated on a test set of 34 eyes. Clinical implications of the OCT-omics prediction model were assessed by decision curve analysis. Performance metrics (sensitivity, specificity, F1 score, and AUC) were calculated.

Results: The logistic, SVM, and BPNN classifiers demonstrated robust discriminative abilities in both the training and test sets. In the training set, the logistic classifier achieved a sensitivity of 0.904, specificity of 0.741, F1 score of 0.887, and AUC of 0.910. The SVM classifier showed a sensitivity of 0.923, specificity of 0.667, F1 score of 0.881, and AUC of 0.897. The BPNN classifier exhibited a sensitivity of 0.962, specificity of 0.926, F1 score of 0.962, and AUC of 0.982. Similar discriminative capabilities were maintained in the test set. The OCT-omics scores were significantly higher in the non-persistent DME group than in the persistent DME group (p < 0.001). OCT-omics scores were also positively correlated with the rate of decline in central subfield thickness after treatment (Pearson's R = 0.44, p < 0.001).

Conclusion: The developed OCT-omics model accurately assesses anti-VEGF treatment response in DME patients. The model's robust performance and clinical implications highlight its utility as a non-invasive tool for personalized treatment prediction and retinal pathology assessment.

Keywords: Anti-VEGF treatment response; Diabetic macular edema; OCT-omics; Prognostic model; Retinal imaging.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Diabetes Mellitus* / drug therapy
  • Diabetic Retinopathy* / diagnostic imaging
  • Diabetic Retinopathy* / drug therapy
  • Humans
  • Intravitreal Injections
  • Machine Learning
  • Macular Edema* / complications
  • Macular Edema* / diagnostic imaging
  • Macular Edema* / drug therapy
  • Radiomics
  • Retrospective Studies
  • Tomography, Optical Coherence / methods
  • Vascular Endothelial Growth Factors

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factors